<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34459281</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1542-6270</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>56</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Annals of pharmacotherapy</Title>
          <ISOAbbreviation>Ann Pharmacother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease.</ArticleTitle>
        <Pagination>
          <StartPage>691</StartPage>
          <EndPage>703</EndPage>
          <MedlinePgn>691-703</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/10600280211040093</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the role of oral anticoagulation in patients with stage 5 chronic kidney disease (CKD-5) or end-stage kidney disease (ESKD).</AbstractText>
          <AbstractText Label="DATA SOURCES" NlmCategory="METHODS">A literature search of PubMed (January 2000 to July 1, 2021), the Cochrane Library, and Google Scholar databases (through April 1, 2021) was performed with keywords <i>DOAC</i> (direct-acting oral anticoagulant) OR <i>NOAC</i> or <i>dabigatran</i> OR <i>rivaroxaban</i> OR <i>apixaban</i> OR <i>edoxaban</i> AND <i>end-stage kidney disease</i> combined with <i>atrial fibrillation</i> (AF) or <i>venous thromboembolism</i> (VTE) OR <i>pulmonary embolism</i> OR <i>deep-vein thrombosis</i>.</AbstractText>
          <AbstractText Label="STUDY SELECTION AND DATA EXTRACTION" NlmCategory="METHODS">Case-control, cohort, and randomized controlled trials comparing DOACs to an active control for AF or VTE in patients with CKD-5 or ESKD and reporting outcomes of stroke, recurrent thromboembolism, or major bleeding were included.</AbstractText>
          <AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Nine studies were included. Efficacy data supporting routine use of warfarin or DOACs in CKD-5 or ESKD are limited. Rivaroxaban and apixaban may provide enhanced safety compared to warfarin in patients with AF. Data for VTE are limited to 1 retrospective study.</AbstractText>
          <AbstractText Label="RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE" NlmCategory="CONCLUSIONS">Because of the paucity of rigorous, prospective studies in CKD-5 or ESKD, OACs should not be broadly used in this population. It is clear that data regarding efficacy of DOACs cannot be reliably and safely extrapolated from the non-ESKD population. Therefore, use of OACs in this population should be individualized.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">If OACs for stroke prevention with AF are deemed necessary, apixaban or rivaroxaban can be considered. DOACs cannot currently be recommended over warfarin in patients with CKD-5 or ESKD and VTE.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Starr</LastName>
            <ForeName>Jessica A</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0003-2704-4372</Identifier>
            <AffiliationInfo>
              <Affiliation>Auburn University, Birmingham, AL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinner</LastName>
            <ForeName>Nathan A</ForeName>
            <Initials>NA</Initials>
            <Identifier Source="ORCID">0000-0003-1938-5951</Identifier>
            <AffiliationInfo>
              <Affiliation>Auburn University, Birmingham, AL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mannis</LastName>
            <ForeName>Melanie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Samford University, Birmingham, AL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stuart</LastName>
            <ForeName>Mary Katherine</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Baptist Princeton Medical Center, Birmingham, AL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Ann Pharmacother</MedlineTA>
        <NlmUniqueID>9203131</NlmUniqueID>
        <ISSNLinking>1060-0280</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DOAC</Keyword>
        <Keyword MajorTopicYN="N">anticoagulation</Keyword>
        <Keyword MajorTopicYN="N">apixaban</Keyword>
        <Keyword MajorTopicYN="N">atrial fibrillation</Keyword>
        <Keyword MajorTopicYN="N">bleeding</Keyword>
        <Keyword MajorTopicYN="N">dialysis</Keyword>
        <Keyword MajorTopicYN="N">stroke</Keyword>
        <Keyword MajorTopicYN="N">thrombosis</Keyword>
        <Keyword MajorTopicYN="N">warfarin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>8</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34459281</ArticleId>
        <ArticleId IdType="doi">10.1177/10600280211040093</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
